Literature DB >> 15296836

Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model.

Masahiro Tsuji1, Mary Ann Wilson, Mary S Lange, Michael V Johnston.   

Abstract

Hypoxic-ischemic encephalopathy (HIE) is a leading cause of mortality and morbidity during the perinatal period, and currently no therapeutic drug is available. Minocycline, an antibiotic, has recently been shown to have neuroprotective effects distinct from its antimicrobial effect in several neurological disorders including ischemic brain injury. We examined the effect of minocycline on neonatal hypoxic-ischemic brain injury by using histologic scoring in both mouse and rat models. Mouse (C57Bl/6) and rat (SD) pups were exposed to a unilateral hypoxic-ischemic insult at 8 and 7 days of age, respectively. Minocycline hydrochloride was administered according to protocols that were reported to provide neuroprotection in adult or neonatal rats. Seven days after the insult, we examined brain injury in Nissl stained sections. Although minocycline ameliorated brain injury in the developing rat, it increased injury in the developing mouse. This detrimental effect in the mouse was consistent across different regions (cortex, striatum, and thalamus), with both single and multiple injection protocols and with both moderate and high-dose treatment (P < 0.05). The mechanism of the contrasting effects in mouse and rat is not clear and remains to be elucidated. Minocycline has been used as an antibiotic in the clinical setting for decades; therefore, it may be considered for use in infants with hypoxic-ischemic brain damage, based on prior reports of neuroprotection in the rat. However, it is important to examine this drug carefully before clinical use in human infants, taking our data in the mouse model into consideration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15296836     DOI: 10.1016/j.expneurol.2004.01.011

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  61 in total

1.  Profile of minocycline neuroprotection in bilirubin-induced auditory system dysfunction.

Authors:  Ann C Rice; Victoria L Chiou; Sarah B Zuckoff; Steven M Shapiro
Journal:  Brain Res       Date:  2010-11-12       Impact factor: 3.252

Review 2.  Microglia Activation and Schizophrenia: Lessons From the Effects of Minocycline on Postnatal Neurogenesis, Neuronal Survival and Synaptic Pruning.

Authors:  Dragos Inta; Undine E Lang; Stefan Borgwardt; Andreas Meyer-Lindenberg; Peter Gass
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

3.  Differential effects of early postinjury treatment with neuroprotective drugs in a mouse model using diffuse reflectance spectroscopy.

Authors:  Ariel Shochat; David Abookasis
Journal:  Neurophotonics       Date:  2015-01-22       Impact factor: 3.593

Review 4.  Pathophysiology and neuroprotection of global and focal perinatal brain injury: lessons from animal models.

Authors:  Luigi Titomanlio; David Fernández-López; Lucilla Manganozzi; Raffaella Moretti; Zinaida S Vexler; Pierre Gressens
Journal:  Pediatr Neurol       Date:  2015-01-31       Impact factor: 3.372

5.  Pomegranate polyphenols and resveratrol protect the neonatal brain against hypoxic-ischemic injury.

Authors:  Tim West; Madeliene Atzeva; David M Holtzman
Journal:  Dev Neurosci       Date:  2007       Impact factor: 2.984

6.  Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess.

Authors:  Tammy Kielian; Nilufer Esen; Shuliang Liu; Nirmal K Phulwani; Mohsin M Syed; Napoleon Phillips; Koren Nishina; Ambrose L Cheung; Joseph D Schwartzman; Jorg J Ruhe
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

7.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

8.  Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS.

Authors:  Eva-Maria Ratai; Jeffrey P Bombardier; Chan-Gyu Joo; Lakshmanan Annamalai; Tricia H Burdo; Jennifer Campbell; Robert Fell; Reza Hakimelahi; Julian He; Patrick Autissier; Margaret R Lentz; Elkan F Halpern; Eliezer Masliah; Kenneth C Williams; Susan V Westmoreland; R Gilberto González
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

9.  Cell-specific roles of GRK2 in onset and severity of hypoxic-ischemic brain damage in neonatal mice.

Authors:  Cora H Nijboer; Cobi J Heijnen; Hanneke L D M Willemen; Floris Groenendaal; Gerald W Dorn; Frank van Bel; Annemieke Kavelaars
Journal:  Brain Behav Immun       Date:  2009-11-22       Impact factor: 7.217

10.  Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke.

Authors:  Noriyuki Matsukawa; Takao Yasuhara; Koichi Hara; Lin Xu; Mina Maki; Guolong Yu; Yuji Kaneko; Kosei Ojika; David C Hess; Cesar V Borlongan
Journal:  BMC Neurosci       Date:  2009-10-06       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.